GoAI
Get started
YD Bio Limited Ordinary Shares logo

YD Bio Limited Ordinary Shares

YDES

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.6521

−$0.1337 · -2.79%

Aug 24, 10:05 AM ET

YDES company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

60

Fair Value

Momentum

19

Strong Down

Sentiment

49

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.

Industry
Biotechnology
Sector
Healthcare
Headquarters
TW
CEO
Ethan Shen
Listed since
Aug 29, 2025
Employees
15

Market position

Day range

Current $4.6521

52-week range

Current $4.6521

Open
$4.56
Previous close
$4.7858
Volume
36.01K
0.37× average
Average volume
97.72K
Average daily volume
Market cap
332.2M USD
Beta
-0.12
Market reference 1
50-day average
$2.5938
+79.36% above average
200-day average
$7.0698
-34.20% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-2.89×
P/B (TTM)
-5.62×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
-0×
Altman Z-score
10.36
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends187%-387%-962%-1536%Gross margin, FY2023: 43.83%Gross margin, FY2024: 30.44%Gross margin, FY2025: -7.06%Operating margin, FY2023: -2.81%Operating margin, FY2024: -286.45%Operating margin, FY2025: -883.31%Net margin, FY2023: 3.87%Net margin, FY2024: -276.58%Net margin, FY2025: -1392.61%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2023 43.83%. Gross margin FY2024 30.44%. Gross margin FY2025 -7.06%. Operating margin FY2023 -2.81%. Operating margin FY2024 -286.45%. Operating margin FY2025 -883.31%. Net margin FY2023 3.87%. Net margin FY2024 -276.58%. Net margin FY2025 -1392.61%.

Income trends

Revenue

596.82K USD+16.94%

Operating income

−5.27M USD-260.60%

Net income

−8.31M USD-488.80%
Income trends across reported periods10.41M USD3.6M USD−3.21M USD−10.01M USDRevenue, FY2023: 350.13K USDRevenue, FY2024: 510.36K USDRevenue, FY2025: 596.82K USDOperating income, FY2021: −1.72M USDOperating income, FY2022: −2.32M USDOperating income, FY2023: −9.85K USDOperating income, FY2024: −1.46M USDOperating income, FY2025: −5.27M USDNet income, FY2021: 8.7M USDNet income, FY2022: 3.79M USDNet income, FY2023: 13.56K USDNet income, FY2024: −1.41M USDNet income, FY2025: −8.31M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2023 350.13K USD. Revenue FY2024 510.36K USD. Revenue FY2025 596.82K USD. Operating income FY2021 −1.72M USD. Operating income FY2022 −2.32M USD. Operating income FY2023 −9.85K USD. Operating income FY2024 −1.46M USD. Operating income FY2025 −5.27M USD. Net income FY2021 8.7M USD. Net income FY2022 3.79M USD. Net income FY2023 13.56K USD. Net income FY2024 −1.41M USD. Net income FY2025 −8.31M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue596.82K USD510.36K USD350.13K USD——
Cost of goods sold638.97K USD355K USD196.69K USD——
Gross profit−42.15K USD155.36K USD153.45K USD——
Research and development1.6M USD491.35K USD———
Selling, general, and administrative3.63M USD1.13M USD160.56K USD2.32M USD1.72M USD
Operating expenses5.23M USD1.62M USD163.29K USD2.32M USD1.72M USD
Interest income80.16K USD11.81K USD290 USD813 USD764 USD
Interest expense—772 USD2.14K USD——
Depreciation and amortization209.56K USD104.74K USD2.45K USD——
Operating income−5.27M USD−1.46M USD−9.85K USD−2.32M USD−1.72M USD
Net income−8.31M USD−1.41M USD13.56K USD3.79M USD8.7M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.12
FY2025
Latest fiscal-year revenue
596.82K USD
FY2025 · +16.94% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.70.24-0.22-0.68FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend656.5K417.77K179.05K-59.68KFY21FY22FY23FY24FY25

YDES news

defenseworld.net

Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ: ABUS - Get Free Report) and YD Bio (NASDAQ: YDES - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the…

Read source
globenewswire.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

The six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada Taipei, Taiwan, July 28, 2026 (GLOBE NEWSWIRE) --…

Read source
globenewswire.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic…

Read source
globenewswire.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic…

Read source
globenewswire.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic…

Read source

YDES peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding YDES

Funds reporting this stock among their holdings, ordered by reported position size.

Fidelity Nasdaq Composite Index ETF logoFidelity Nasdaq Composite Index ETFONEQ
Market value
103.87K
Weight
—
AUM
10.35B USD
Expense ratio
0.21%
Price / 1D
$102.21-0.91%

Continue in GoAI

Research YDES

research.disclaimer